Lilly Targets Mild Covid-19 Cases With New Antibody Study (1)

One of the first promising treatments for patients with mild cases of Covid-19 moved into mid-stage clinical testing Tuesday, to see if Eli Lilly and Co’s lab-created antibodies can shorted the severity of the disease.

The National Institutes of Health announced two separate clinical trials to test monoclonal antibodies—proteins developed in the lab to block the virus from infecting the body—for patients with earlier stages of Covid-19, Anthony S. Fauci, the nation’s leading infectious disease expert, said during a press call.

Gilead’s experimental antiviral remdesivir and the anti-inflammatory steroid dexamethasone have shown promise for patients with advanced ...